About GRIP Molecular
GRIP Molecular Technologies develops a diagnostic test platform built on a CRISPR protease enzyme. The test detects pathogen RNA, amplifies the signal and returns results in minutes. Readouts can be lateral flow assays, electrochemical tests or simple colorimetric assays. GRIP aims the platform at point-of-care and point-of-need settings. It invites diagnostics manufacturers, research groups and public health organizations to get in touch.
The company is based in St. Paul, Minnesota. Bruce Batten is the founder and chief scientific officer, and Edward Gillen is chief executive officer. Edward Ludwig is board chairman, and Richard Minicus is chief financial officer. Michael Osterholm, a University of Minnesota regents professor, is clinical advisor.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 15, 2023 | May 30, 2023 | $500,000fully sold | 1 | $500K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Nov 30, 2020 | Dec 11, 2020 | $100,000target not set | 1 | $100K | EquityRule 506(b) | Form D ↗ |
| Dec 16, 2019 | Dec 20, 2019amended Oct 29, 2026 | $11,785,460of $21.0M target | 41 | $287K | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗5 earlier filings |
| Total, three offerings | $12,385,460 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed GRIP Molecular
GRIP Molecular Technologies of St. Paul, Minnesota, builds a CRISPR protease platform for rapid infection tests. It targets clinics and other point-of-care settings that lack fast molecular testing. Its chairman, chief executive officer and chief financial officer each have Becton Dickinson in their careers. Together they bring decades of experience in the medical industry.
The problem it targets
GRIP's view is that quick, accurate and affordable testing is hard to find where it is needed most. GRIP puts the global market for point-of-care tests for sexually transmitted, urinary tract and upper respiratory infections at over $2 billion a year. PCR is the gold-standard molecular test, but it is often centralized, costly and slow to deploy. As a result, clinics, urgent care centers and community health programs lack a fast way to spot these infections and stop their spread.
What the product does
The engine of the platform is a CRISPR protease. It uses stable proteins as the reporter substrates. GRIP's case is that this avoids false positives caused by nucleases. The enzymes work at room temperature. The test can detect bacteria, viruses or fungi. Samples can be saliva, swabs or urine. The protein-based reagents are built to fit proven immunoassay pipelines.
Who backs it
Board chairman Edward Ludwig once served as president and chief executive officer of Becton, Dickinson and Company. Chief executive officer Edward Gillen spent 23 years at BD and most recently led the start-up Medality Medical. Chief financial officer Richard Minicus spent 21 years at BD and Pfizer in medical technology business development. He also spent nine years in banking at Merrill Lynch and JP Morgan. Founder Bruce Batten has held chief-level roles at four technology startups, founding two before launching GRIP. GRIP is exploring collaborations with angel investors, family offices, strategic investors and venture capital firms.
We wrote this summary from public statements by GRIP Molecular and its investors. It is not investment advice.
GRIP Molecular in the News
Leadership Team
Executive officers and directors listed on GRIP Molecular's Form D filed May 30, 2023.
Sources
- SECGRIP Molecular Technologies Inc. Form D/A, filed May 16, 2025
- SECGRIP Molecular Technologies Inc. Form D/A, filed May 30, 2023
- SECGRIP Molecular Technologies Inc. Form D/A, filed Jul 25, 2022
- SECGRIP Molecular Technologies Inc. Form D/A, filed Jul 10, 2020
- SECGRIP Molecular Technologies Inc. Form D, filed Dec 20, 2019
- SECGRIP Molecular Technologies Inc. filing history
- CompanyGRIP Molecular Technologies team page
- CompanyGRIP Molecular Technologies contact page